Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-09-25 06:03Group 1 - The innovative drug sector in A-shares and H-shares continues to rise, with notable stocks such as Aosaikang and Junshi Biosciences showing significant gains [1] - Aosaikang's subsidiary has completed the first patient dosing in a Phase III clinical trial for a new drug targeting advanced non-small cell lung cancer [1] - Heng Rui Medicine has licensed its innovative drug to Glenmark Specialty for an upfront payment of $18 million and potential milestone payments totaling up to $1.093 billion [1] Group 2 - The Hong Kong innovative drug ETF (513120) has seen a rise of over 1%, with leading stocks like Junshi Biosciences and Rongchang Bio leading the gains [2] - The innovative drug ETF (515120) has also experienced a nearly 2% increase, with significant inflows totaling 699 million yuan over the past 20 trading days [2] - Tianfeng Securities highlights that the Chinese innovative drug industry is forming a pyramid structure led by top enterprises, indicating strong sustainability in the sector [2] Group 3 - The Hong Kong innovative drug ETF (513120) allows T+0 trading, enhancing liquidity and capital efficiency for investors [3] - The innovative drug ETF (515120) closely tracks the innovative drug industry index in A-shares, covering various aspects of drug development and sales [3]